Clinical Trial

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose（SAD） and Multiple ascending dose（MAD）. Subjects will receive at least 1 dose of NCR101.
Trial Details
NCT Number NCT06825169
Lead Sponsor Nuwacell Biotechnologies Co., Ltd.
Conditions Interstitial Lung Disease (ILD)
Enrollment 30 participants
Start Date 2025-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-13